Rairigh R L, Le Cras T D, Ivy D D, Kinsella J P, Richter G, Horan M P, Fan I D, Abman S H
Pediatric Heart Lung Center, Department of Pediatrics, University of Colorado School of Medicine, Denver, Colorado 80218, USA.
J Clin Invest. 1998 Jan 1;101(1):15-21. doi: 10.1172/JCI1228.
Nitric oxide (NO) produced by NO synthase (NOS) modulates fetal pulmonary vascular tone and contributes to the fall in pulmonary vascular resistance (PVR) at birth. Although the inducible (type II) NOS isoform is present in human and rat fetal lungs, it is uncertain whether type II NOS activity contributes to vascular NO production in the fetal lung. To determine whether type II NOS is present in the ovine fetal lung and to study the potential contribution of type II NOS on the regulation of basal PVR in the fetus, we measured the hemodynamic effects of three selective type II NOS antagonists: aminoguanidine (AG), 2-amino-5,6-dihydro-6-methyl-4H-1,3 thiazine (AMT), and S-ethylisothiourea (EIT). Studies were performed after at least 72 h of recovery from surgery in 19 chronically prepared fetal lambs (133+/-3 d; 147 d, term). Brief intrapulmonary infusions of AG (140 mg), AMT (0.12 mg), and EIT (0.12 mg) increased basal PVR by 82, 69, and 77%, respectively (P < 0.05). The maximum increase in PVR occurred within 20 min, but often persisted up to 80 min. These agents also increased mean aortic pressure but did not alter the pressure gradient between the pulmonary artery and aorta, suggesting little effect on tone of the ductus arteriosus. Acetylcholine-induced pulmonary vasodilation remained intact after treatment with selective type II NOS antagonists, but not after treatment with the nonselective NOS blocker, nitro-L-arginine. Using Northern blot analysis with poly(A)+ RNA, we demonstrated the presence of two mRNA transcripts for type II NOS (4.1 and 2.6 kb) in the fetal lung. We conclude that the type II NOS isoform is present in the ovine fetal lung, and that selective type II NOS antagonists increase PVR and systemic arterial pressure in the late-gestation fetus. We speculate that type II NOS may play a physiological role in the modulation of vascular tone in the developing fetal lung.
一氧化氮合酶(NOS)产生的一氧化氮(NO)可调节胎儿肺血管张力,并促使出生时肺血管阻力(PVR)下降。虽然诱导型(II型)NOS亚型存在于人和大鼠的胎儿肺中,但II型NOS活性是否有助于胎儿肺血管中NO的产生尚不确定。为了确定II型NOS是否存在于绵羊胎儿肺中,并研究II型NOS对胎儿基础PVR调节的潜在作用,我们测量了三种选择性II型NOS拮抗剂的血流动力学效应:氨基胍(AG)、2-氨基-5,6-二氢-6-甲基-4H-1,3噻嗪(AMT)和S-乙基异硫脲(EIT)。在19只长期制备的胎儿羔羊(133±3天;足月为147天)术后至少恢复72小时后进行研究。肺内短暂输注AG(140毫克)、AMT(0.12毫克)和EIT(0.12毫克)分别使基础PVR增加82%、69%和77%(P<0.05)。PVR的最大增加在20分钟内出现,但通常持续长达80分钟。这些药物还增加了平均主动脉压,但未改变肺动脉和主动脉之间的压力梯度,表明对动脉导管张力影响很小。用选择性II型NOS拮抗剂治疗后,乙酰胆碱诱导的肺血管舒张仍然存在,但用非选择性NOS阻滞剂硝基-L-精氨酸治疗后则不存在。通过对聚腺苷酸加尾RNA进行Northern印迹分析,我们证实在胎儿肺中存在II型NOS的两种mRNA转录本(4.1和2.6 kb)。我们得出结论,II型NOS亚型存在于绵羊胎儿肺中,并且选择性II型NOS拮抗剂可增加妊娠晚期胎儿的PVR和体循环动脉压。我们推测II型NOS可能在发育中的胎儿肺血管张力调节中发挥生理作用。